Bracket acquires mProve, both committed to ‘BYOD’ in clinical trials, says CEO

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/oatawa)
(Image: Getty/oatawa)

Related tags Food and drug administration

“Bring Your Own Device” (BYOD) in clinical trials will be a “critical component” of future research says Bracket CEO following the company’s acquisition of mProve Health.

The clinical trial technology and service provider announced the acquisition of mProve Health​ yesterday. The transaction as supported by the private equity firm and Bracket owner​, Genstar Capital.

mProve has an aggressive technology roadmap and numerous new products and features due to be released in the coming months​,” Jeff Lee, CEO, mProve Health, told

mProve Health is mobile technology​ provider offering mobile solutions for patient recruitment, patient engagement, and electronic clinical outcome assessments (eCOA).

mProve’s patient engagement tools are a natural complement to our existing eCOA platform. Our first priority will be working with sponsors to bring these two together​,” Jeff Kinell, CEO, Bracket told

Moving forward as of now mProve will operate with some independence, he explained. The companies are already working with several sponsor companies on clinical trials together, ​Kinell said.

Bracket and mProve are committed to BYOD,”​ added Kinell. “I think there is a clear consensus from stakeholders that this will be a critical component of research​ in the future​.”

Kinell explained the US Food and Drug Administration (FDA) has been especially receptive to this, ​noting that Lee from mProve has already met with the agency to discuss best practices.

“This investment is a reflection of our belief that this is an important and growing area,​” he added.

Although patient engagement is an emerging area, the data from trials that are leveraging this approach are tremendous. mProve has data showing that patient retention goes up, medication adherence is high, patient compliance with diaries is better, when comprehensive patient engagement programs are put in place​.”

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more